Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of Buprenorphine and Naloxone in Opiate Addicts - 4

This study has been completed.
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: May 1995
The purpose of this study is to evaluate the behavioral and physiological effects of buprenorphine and naloxone, both alone and in combination.

Condition Intervention Phase
Opioid-Related Disorders
Substance-Related Disorders
Drug: Buprenorphine
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Effects of Buprenophine and Naloxone in Opiate Addicts

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
Study Start Date: November 1994

Ages Eligible for Study:   21 Years to 59 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000355

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Pennsylvania
Principal Investigator: Charles O'Brien, M.D., Ph.D. PDVAMC Treatment Research Center
  More Information Identifier: NCT00000355     History of Changes
Other Study ID Numbers: NIDA-3-0012-4  Y01-3-0012-4 
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Opioid-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on October 21, 2016